Author

Oyeronke Ayansola

Observed names: Ayansola, Oyeronke Temidayo, Oyeronke T. Ayansola, Oyeronke Temidayo Ayansola

Institutions: University Health Network, University of Toronto, Princess Margaret Cancer Centre

Observed institutions: University Health Network, University of Toronto, York University, Stellenbosch University, Princess Margaret Cancer Centre, Nigeria Centre for Disease Control, Nottingham Trent University, University of KwaZulu-Natal

OpenAlex ID: A5061245848

Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus

2022 · Christian Happi, Ifedayo Adetifa, et al. · PLoS Biology · 339

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

2022 · Houriiyah Tegally, James E. San, et al. · Science · 179

Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria

2023 · Idowu B. Olawoye, Paul E. Oluniyi, et al. · Nature Communications · 28

Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF)

2024 · Sungji Cho, Keith Dadson, et al. · Biomedicine & Pharmacotherapy · 18

SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: Implications for epidemic control

2023 · Oluwapelumi Olufemi Adeyemi, Nnaemeka Darlington Ndodo, et al. · PLoS ONE · 4

Leptin-Enhanced JAK-STAT Signaling in Acute Myeloid Leukemia-Derived Mesenchymal Stromal Cells and Its Implications for Disease Progression

2024 · Muzaffar Bhatti, Anthea Travas, et al. · Blood · 2

Viral adaptation to alternating hosts and associated allelic variants

2019 · Oyeronke Ayansola, Benjamin Dickins, et al. · Access Microbiology · 1

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients

2025 · Dennis Kim, Yael Morgenstern, et al. · Research Square

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia

2025 · Yael Morgenstern, Oyeronke Ayansola, et al. · Blood

Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

2025 · Yael Morgenstern, Amirthagowri Ambalavanan, et al. · Blood

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring

2025 · Yael Morgenstern, Gopila Gupta, et al. · Blood

Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients

2024 · May Chiu, Maria Agustina Perusini, et al. · Blood

Adaptation of bacteriophage to variable environments

2020 · Oyeronke T. Ayansola · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository)

Works count: 14

Citation count: 571

H-index: 4

I10-index: 4